Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Moderna (NasdaqGS:MRNA) with a Neutral recommendation. Analyst Price Forecast Suggests 62.09% Upside As of March 4, 2025, the ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine demand and pipeline uncertainty. With shares trading near 5-year lows and ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna stock has surged more than 20% this ... Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments.

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial ...

All three shares are in the red for 2025 after a tough 2024. Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market.